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ABSTRACT
Objectives. Our main aim was to assess the quality of life (QoL) and treatment
satisfaction (TS) of subjects with LADA (latent autoimmune diabetes of the adult)
and compare these measures with those of patients with other diabetes types, i.e., type
1 (T1DM) and type 2 diabetes mellitus (T2DM).
Methods. This was a cross-sectional study with a total of 48 patients with LADA, 297
patients with T2DM and 124 with T1DM. The Audit of Diabetes-Dependent Quality of
Life (ADDQoL-19) questionnaire and the Diabetes Treatment Satisfaction Question-
naire (DTSQ) were administered. Relevant clinical variables were also assessed. The
data analysis included comparisons between groups and multivariate linear models.
Results. The LADA patients presented lower diabetes-specific QoL (p= 0.045) and
average weighted impact scores (p= 0.007) than the T2DM patients. The subgroup
of LADA patients with diabetic retinopathy (DR) who were treated with insulin had a
lowerADDQoL averageweighted impact score than the other diabetic groups. Although
the overall measure of TS was not different between the LADA and T2DM (p= 0.389)
and T1DM (p= 0.091) groups, the patients with LADA showed a poorer hyperglycemic
frequency perception than the T2DM patients (p< 0.001) and an improved frequency
of hypoglycemic perception compared with the T1DM patients (p= 0.021).
Conclusions. The current findings suggest a poorer quality of life, especially in terms of
DR and insulin treatment, among patients with LADA comparedwith thosewith T1DM
and T2DM. Hyperglycemia frequency perception was also poorer in the LADA patients
than in the T1DM and T2DM patients. Further research with prospective studies and
a large number of patients is necessary.
Subjects Diabetes and Endocrinology, Nursing, Public Health
Keywords Treatment satisfaction, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Quality of
life, Autoimmune diabetes
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INTRODUCTION
Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune
diabetes that presents an initial type 2 diabetes mellitus (T2DM) phenotype combined with
diabetes-related autoantibodies (Leslie et al., 2016). At diagnosis, patients do not require
insulin therapy and are often classified as T2DM patients (Hawa et al., 2013; Stenstrom et
al., 2005). Patients with LADA are younger and leaner that T2DM patients (Hawa et al.,
2013; Stenstrom et al., 2005). They usually have a lower body mass index (BMI), serum
triglycerides (TG), waist circumference (WC), waist-to-hip ratio, and blood pressure (BP)
and higher HDL cholesterol levels than the T2DM population (Fourlanos et al., 2005;Hawa
et al., 2009; Hawa et al., 2013; Isomaa et al., 1999; Mollo et al., 2013). The cardiovascular
risk profile of LADA is intermediate, falling between that of type 1 and type 2 diabetes.
Additionally, these patients show lower residual endogenous insulin secretion and progress
more rapidly to insulin treatment with worse glycemic control (Fourlanos et al., 2005;
Hawa et al., 2009; Isomaa et al., 1999; Mollo et al., 2013; Hernandez et al., 2015).
Quality of life (QoL) is a subjective measure of health and well-being related to disease.
It includes psychosocial features, physical functioning, mobility and personal care (Esteban
y Peña et al., 2010). The aim of measuring QoL is to provide a more comprehensive,
integral, precise and valid evaluation of patients’ health status (Speight, Reaney & Barnard,
2009). Treatment satisfaction (TS) is an individual subjective measure that assesses the
patients’ experience of treatment processes and results, including ease of use, side effects
and efficacy (Hervás et al., 2002). TS can be influenced by demographic characteristics
such as age, educational level and salary (Villar-López et al., 2009). The development of the
disease, information regarding treatment, therapy availability and costs are also associated
with TS (Villar-López et al., 2009). Furthermore, diabetes mellitus reportedly has a negative
impact QoL, but TS is optimal in this population (Speight, Reaney & Barnard, 2009).
Previous studies have investigated the QoL and TS of patients with type 1 diabetes
mellitus (T1DM) and T2DM, but not those with LADA (Ahola et al., 2010; Bradley et
al., 2011; Depablos-Velasco et al., 2014; Nicolucci et al., 2009; Oliva, Fernandez-Bolanos &
Hidalgo, 2012). The PANORAMA study found that T2DM patients with poor glycemic
control, complex treatments and severe hypoglycemic episodes showed poorer QoL
compared with patients without these factors (Bradley et al., 2011; Depablos-Velasco et
al., 2014). Other studies observed that QoL and treatment satisfaction were lower with
increasing age, female sex, lower education level, insulin treatment and obesity, the presence
of diabetic comorbidities, poorer glycemic control and lower socioeconomic status (Ahola
et al., 2010; Nicolucci et al., 2009; Oliva, Fernandez-Bolanos & Hidalgo, 2012).
As the diagnosis of LADA among subjects with type 2 diabetes is usually delayed, which
may increase the disease burden, we hypothesized that LADA patients might have a lower
QoL and TS than their counterparts with T2DM; however, LADA is an autoimmune form
of diabetes that usually evolves into a phenotype closely related to that of classical type
1 diabetes. Furthermore, the identification of LADA subjects may be relevant from the
clinical point of view.
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To our knowledge, no studies have evaluated QoL and TS in subjects with LADA.
Therefore, the primary objective of this study was to assess QoL and TS in patients with
LADA and to compare these measures with those of T2DM and T1DM patients. We also
evaluated the factors related to both QoL and TS in the study subjects.
MATERIALS AND METHODS
The study design was observational and cross-sectional. LADA was defined as diabetes
diagnosed in individuals over 30 years of age with a positive test for glutamic acid
decarboxylase (GAD) antibodies and without the need for insulin treatment during the first
six months after diagnosis (Leslie et al., 2008; Mollo et al., 2013). Patients with T1DM and
T2DM were diagnosed according to the current standard diagnostic criteria, as described
previously (Mollo et al., 2013). The inclusion criteria for the three groups of patients were
as follows: a diagnosis of diabetes mellitus with a disease duration of more than one
year; age greater than 18 years; absence of disability due to macrovascular complications
(including a history of diabetic foot disease); and absence of macroalbuminuria (defined
as urine albumin-to-creatinine ratio >300 mg/g) or renal failure (estimated glomerular
filtration rate <60 ml/min/1.73 m2). The exclusion criteria were as follows: conditions
that could affect the results, such as dementia, mental diseases, hearing and languages
problems, pregnancy and disability due to cardiovascular diseases. Dementia and mental
diseases had to be diagnosed by a physician and could be determined using the registered
clinical records of the patient’s general practitioner. No screening tools for detecting
initial cognitive impairment were used. All included patients had an estimated glomerular
filtration rate >60 ml/min, except for two LADA participants who had a glomerular
filtration rate between 30 and 59 ml/min. Two patients in the T1DM group had previous
cerebrovascular events, and one patient had bilateral femoral stenosis; none of the patients
had any disability. The study was approved by the Ethics Committee of Hospital Arnau
de Vilanova (Ethical Application Ref: CEIC 1079 and Ref: PI-13-095). Written informed
consent was obtained from all of the subjects.
Clinical variables
Trained researchers (MG-C and NA) conducted personal interviews with each of the
patients and reviewed the medical records to collect the data regarding the variables
of interest. Anthropometric measures were determined according to standard criteria.
Laboratory tests and blood pressure were measured using standard procedures as
previously described (Alcubierre et al., 2014). Hypertension and dyslipidemia were defined
if the participant was undergoing pharmacological treatment for these conditions.
Microalbuminuria was defined as an albumin creatinine ratio >30 mg/g. Physical
activity was assessed using a validated method by Bernstein, Morabia & Sloutskis (1999);
participants were classified as engaging in regular exercise if they performed any physical
activity that required at least ≥4 METS (The Metabolic Equivalent) of brisk walking for
30 min or more and as sedentary if they did not perform any daily physical activity or if
they engaged less than 30 min of physical activity per day (Bernstein, Morabia & Sloutskis,
1999; Cabrera de León et al., 2007).
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Quality of life
QoL was assessed through the Audit of Diabetes-Dependent Quality of Life (ADDQoL-
19), a disease-specific QoL questionnaire designed and validated in diabetic Spanish
subjects (Bradley et al., 2011; Bradley et al., 1999; Depablos-Velasco et al., 2014) (File S1).
This questionnaire consists of 21 items, of which 19 are related to specific life domains and
are scored on a 5-point scale. The impact of diabetes on each domain is weighted according
to the importance of the domain to the patient’s QoL and is reported as the average
weighted impact score. These scores can range from +9 (maximum positive impact) to
−3 (maximum negative impact). The first two items are general and are scored separately.
The first item measures current QoL and is scored from +3 (excellent) to −3 (very bad).
The second item measures diabetes-specific QoL and ranges from −3 (maximum negative
impact) to +1 (maximum positive impact). Moreover, five of the 19 items that may not
have importance for some patients are included in a preliminary question that can be
ignored if not applicable. All the questionnaires were administered individually by two
trained interviewers (MG-C and NA.).
Treatment satisfaction
TSwas determined by a diabetes-specific questionnaire, theDiabetes Treatment Satisfaction
Questionnaire status-version (DTSQ-s) (Bradley, 1994), that has been validated for the
Spanish diabetic population (Gomis et al., 2006) (File S2). This questionnaire consists of
eight items scored on a 6-point scale. The final score is weighted according to six items
with total scores ranging from 36 (very satisfied) to 0 (very unsatisfied). The two remaining
items measure the frequency of hyperglycemia and hypoglycemia, respectively, and are
scored on a scale from 0 (never) to 6 (always).
Sample size
To our knowledge, no previous studies have reported QoL and TS in patients with LADA.
Additionally, the number of subjects with LADA is limited at the local level, and we aimed
to recruit all available patients.
Statistical analysis
The statistical analysis included the comparability among the groups of subjects with
diabetes (LADA, T2DM and T1DM) and multivariate linear regression models’ estimation
of the variability of the overallmean score forQoL and the presentQoL anddiabetes-specific
QoL items provided by the ADDQoL questionnaire. The TS score and the hyperglycemia
and hypoglycemia frequencies were also fitted in multivariate linear regression models to
identify differences between the types of diabetes after adjustment for significantly related
patient characteristics. The comparison of QoL and TS between the diabetic groups was
stratified by the median of the two groups. In the multivariate linear regression models,
LADA patients undergoing insulin treatment were used as the reference group in all of
the analyses. The comparability analysis included Pearson’s chi-squared test (or Fisher’s
exact test in the case of any expected frequency lower than 5) to compare the distribution
of qualitative characteristics. The Kruskal-Wallis test was performed to compare the
distribution of quantitative characteristics, including pairwise comparisons to adjust for
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multiple testing according to the Benjamini & Hochberg method; furthermore, these
characteristics were described by median and interquartile intervals for each diabetic
group. The significance level was set at 0.05. The statistical software R version 3.3.2 (R Core
Team, 2016) was used for the analyses.
RESULTS
We had previously identified a total of 106 LADA patients in the local cohort of the only
reference hospital in Lleida (North-Eastern Spain). This hospital is the public reference
center for specialized diabetes care for the health care district of Lleida. From this sample,
20 participants were excluded after the initial screening based on the exclusion criteria.
From a sample of 86 LADA patients who were contacted to participate in the study, 51
participants initially accepted, and an additional three patients were excluded. Thus, 48
LADA patients were included in the study. From a sample of 170 T1DM patients who
were contacted to participate in the study, a total of 127 agreed to participate, and 3 were
excluded for pregnancy, yielding a final sample of 124 patients. As a comparison with
T2DM, we used the entire group of 297 patients with T2DM who had been included in a
previous study of QoL conducted at the same center (Alcubierre et al., 2014).
The comparison between the patients with LADA included in the study and those who
refused to participate (n= 35) revealed no differences in clinical characteristics except for
a lower frequency of insulin treatment in the non-participant group (72%; p= 0.049 for
the comparison with the LADA patients included in the current study).
The clinical and demographic characteristics of the study groups are shown in Table 1.
The LADA patients had an intermediate cardiovascular risk profile in terms of adiposity,
lipids and blood pressure compared with the T2DM and T1DM groups. The patients with
LADA were older than those with T1DM (p< 0.001). The duration of diabetes in the
LADA group was longer (10.7 years) than that of the T2DM group (8 years) and shorter
than that of the T1DM group (20.5 years; p< 0.001). The frequency of diabetic retinopathy
(DR) was 22.9% in the LADA group, 49.8% in the T2DM group and 40.3% in the T1DM
group (p= 0.001). There were no differences in glycated hemoglobin (HbA1c) among the
3 groups (p= 0.689).
Quality of life
The scores for current QoL did not differ among the 3 study groups (p= 0.503; Table 2);
however, there was a higher proportion of patients with negative diabetes-specific QoL in
the LADA group (70.8%) than in the T2DM group (52.9%; p= 0.045). Furthermore, more
subjects with LADA had a negative average weighted impact score (60.4%) compared with
the T2DM patients (37.7%; p= 0.007). Concerning these QoL measures, we could not find
differences between the LADA and T1DM patients.
The multivariate linear model of the diabetes-specific QoL score revealed a significant
interaction with insulin treatment, as indicated in Table 3. The results are expressed using
the group of insulin-treated patients with LADA as the reference group. The LADA and
T2DM subjects without insulin treatment showed a higher diabetes-specific QoL than the
reference group (p= 0.004 and p< 0.001, respectively), whereas there were no differences
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Table 1 Clinical characteristics of the study groups.




Age (years) 62 [53.8;70.2] 60 [52.0;68.0] 46 [37.0;53.0] <0.001 0.118 <0.001
Sex, male 26 (54.2) 151 (50.8) 57 (46.0) 0.543
Education level <0.001 0.181 0.012
<Primary 3 (6.3) 38 (12.8) 17 (13.7)
Primary 24 (50.0) 169 (56.9) 31 (25.0)
Secondary 18 (37.5) 69 (23.2) 54 (43.5)
Graduate or higher 3 (6.3) 21 (7.1) 22 (17.7)
Smoking 0.891
Non-smoker 24 (50.0) 139 (47.3) 57 (46.0)
Smoker, current 11 (22.9) 62 (21.1) 31 (25.0)
Smoker, former 13 (27.1) 93 (31.6) 36 (29.0)
Physical activity 0.052
Sedentary 13 (27.1) 114 (38.4) 34 (27.4)
Regular physical activity 35 (72.9) 183 (61.6) 90 (72.6)
Diabetes duration (years) 10.7 [6.5;16.7] 8 [4.0;15.0] 20.5 [14.0;30.2] <0.001 0.035 <0.001
BMI (kg/m2) 27.1 [24.1;30.4] 30.6 [28.1;34.7] 24.6 [22.5;27.2] <0.001 <0.001 0.001
Waist (centimeters) 96.7± 15.5 106± 11.8 87.7± 12.8 <0.001 <0.001 <0.001
Hypertension 26 (54.2) 168 (56.6) 41 (33.1) <0.001 0.878 0.027
Systolic blood pressure (mmHg) 134 [124.0;148.0] 139 [127.0;150.0] 127 [113.0;139.0] <0.001 0.220 0.017
Diastolic blood pressure (mmHg) 73 [69.0;79.0] 77 [70.0;84.0] 73 [65.0;78.2] <0.001 0.126 0.235
Dyslipidemia 34 (70.8) 131 (44.1) 55 (44.4) 0.002 0.003 0.005
Diabetic retinopathy 11 (22.9) 148 (49.8) 50 (40.3) 0.001 0.003 0.075
Microalbuminuria 11 (23.4) 43 (14.5) 11 (9.1) 0.051
Insulin treatment 43 (89.6) 97 (32.7) 124 (100.0) <0.001 <0.001 0.001
HbA1c (%) 7.5 [6.9;8.2] 7.6 [6.8;8.5] 7.6 [7.0;8.1] 0.689
Total cholesterol (mg/dL) 176 [155.0;202.0] 181 [163.0;205.0] 182 [165.0;202.0] 0.553
HDL-c (mg/dL) 58.5 [40.8;70.2] 48 [41.8;59.0] 63 [53.9;74.0] <0.001 0.040 0.011
LDL-c (mg/dL) 101 [84.0;123.0] 106 [87.2;128.0] 102 [89.6;116.0] 0.391
Triglycerides (mg/dL) 91.5 [66.8;134.0] 117 [83.0;167.0] 65.5 [53.8;81.2] <0.001 0.003 <0.001
Notes.
*p-value for comparison between groups.
LADA, latent autoimmune diabetes of adult; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; BMI, body mass index; HbA1c, glycated haemoglobin; HDL-
c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
Data are median [interquartile], n (%) or means± SD.
between the patients with T1DM and insulin-treated T2DM patients. Additionally, the
presence of hypertension, longer disease duration and a larger waist circumference had a
negative impact on diabetes-specific QoL.
Concerning the ADDQoL average weighted impact score, we found a significant
interaction between DR, the study group (i.e., type of diabetes) and insulin treatment
(Table 4). Insulin-treated LADA subjects showed a poorer average weighted impact score
than their corresponding type 2 non-insulin-treated counterparts (p< 0.001). Additionally,
T2DM patients with DR and with (p= 0.01) or without (p= 0.03) concomitant insulin
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Table 2 Descriptive analysis for the Audit of Diabetes Dependent Quality of Life (ADDQoL) results of the study groups.
Items LADA (N = 48)
n (%)
T2DM (N = 297)
n (%)







[−3,2) 42 (87.5) 242 (81.5) 99 (79.8)
[2,3] 6 (12.5) 55 (18.5) 25 (20.2)
Diabetes-specific QoL <0.001 0.045 0.634
[−3,0) 34 (70.8) 157 (52.9) 94 (75.8)
[0,2] 14 (29.2) 140 (47.1) 30 (24.2)
Average weighted impact score <0.001 0.007 0.069
[−6.526,−0.842) 29 (60.4) 112 (37.7) 94 (75.8)
[−0.842,0.316] 19 (39.6) 185 (62.3) 30 (24.2)
Notes.
The groups are stratified by medians.
*p-value for comparison between groups.
QoL, quality of life; LADA, latent autoimmune diabetes of adult; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus.
Table 3 Multivariate linear regression for the Audit of Diabetes Dependent Quality of Life (ADDQoL)
diabetes-specific QoL score.
Coefficients Estimate Standard error p value
Intercept 0.278998 0.407968 0.490
T2DM* without insulin 0.815249 0.154823 <0.001
LADA* without insulin 1.187429 0.415424 0.004
T2DM* insulin 0.238438 0.168811 0.160
T1DM 0.024457 0.164031 0.880
Hypertension −0.310550 0.089091 0.001
HbA1c −0.070135 0.035407 0.050
Disease duration −0.010606 0.004989 0.030
Waist circumference −0.008147 0.003458 0.020
Notes.
Multiple R-squared: 0.2284 (27 cases with missing information for any variable in the model).
Reference group: LADA patients receiving insulin treatment.
*Indicates the existence of interactions between variables.
LADA, latent autoimmune diabetes of adult; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; HbA1c, gly-
cated haemoglobin.
treatment and T1DM patients with DR (p= 0.03) had a better average weighted impact
score than LADApatients undergoing insulin treatment. The presence of DR, longer disease
duration, lower education level (less than a primary education) and former smoking had
a negative impact on the average weighted impact score. Nevertheless, physical activity
was positively related to this measure of QoL (p= 0.010). Furthermore, using the LADA
patients undergoing insulin treatment with or without DR as reference groups, we could
estimate the combined coefficients using the same model (Table S1). These analyses
showed that LADA subjects with DR who were treated with insulin showed a lower QoL
than any other combination of diabetes type, insulin treatment and DR. Furthermore, the
LADA patients undergoing insulin treatment without DR had a lower QoL than the T2DM
patients without insulin treatment either with (p= 0.006) or without DR (p< 0.001).
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Table 4 Multivariate linear regression for the Audit of Diabetes Dependent Quality of Life (ADDQoL)
average weighted impact score.
Coefficients Estimate Standard error p value
Intercept −1.29375 0.21782 <0.001
T2DM* without insulin 0.95200 0.20699 <0.001
LADA* without insulin 1.06176 0.64037 0.100
T2DM* insulin 0.10006 0.31884 0.750
T1DM −0.04103 0.22328 0.850
DR −1.25952 0.40942 0.002
Disease duration −0.01674 0.00663 0.010
No education** −0.45008 0.15383 0.004
Physical activity 0.27361 0.10539 0.010
Smoker, current −0.21031 0.12937 0.100
Smoker, former −0.30882 0.11674 0.008
T2DM* without insulin* DR 0.92912 0.43927 0.030
LADA* without insulin* DR 1.10620 1.05301 0.290
T2DM* insulin* DR 1.23910 0.49206 0.010
T1DM* DR 0.98320 0.44443 0.030
Notes.
Multiple R-squared: 0.2895 (six cases with missing information for any variable in the model).
Reference group: LADA patients receiving insulin treatment.
*Indicates the existence of interactions between variables.
**‘‘No education’’ identifies patients who did not complete compulsory education.
LADA, latent autoimmune diabetes of adult; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; DR, diabetic
retinopathy.
Treatment satisfaction
The proportion of subjects with a lower DTSQ final score differed among the study
groups: LADA, 60.4%; T2DM, 52.5%; and T1DM, 41.9% (p= 0.049). However, individual
paired comparisons between the groups did not yield statistically significant differences
(Table 5). The multivariate linear regression analysis of the DTSQ final score revealed
no differences between the different combinations of groups according to diabetes type
and insulin-treatment (Table S2). Physical activity had a positive impact (p= 0.001) and
former smoking had a negative impact on the DTSQ final score (p= 0.01).
Concerning another measure of TS, the proportion of patients with a perception
of increased hyperglycemia frequency was higher in the LADA group (87.5%) than in
the T2DM (53.9%) and T1DM groups (71%; p < 0.001 and p= 0.039, respectively).
The multivariate linear regression analysis found an interaction between the type of
diabetes and insulin treatment (Table S3). The insulin-treated LADA patients had a higher
hyperglycemia frequency perception than the T1DM (p= 0.04) and insulin-treated T2DM
subjects (p= 0.05). Physical activity was associated with a lower hyperglycemia perception
frequency (p= 0.002). Additionally, DR and higher HbA1c were associated with higher
hyperglycemia frequency perception (p= 0.05 and p< 0.001, respectively).
Finally, the proportion of patients with higher hypoglycemia frequency perception
differed among the groups (p< 0.001; Table 5). A higher proportion of patients with
T1DM (55.6%) than patients with LADA (33.3%) reported a high frequency of perceived
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Table 5 Results of the variables corresponding to the Diabetes Treatment Satisfaction Questionnaire (DTSQ) in the different study groups.
Items LADA (N = 48)
n (%)
T2DM (N = 297)
n (%)






Hyperglycemia <0.001 <0.001 0.039
frequency perception
0–2 6 (12.5) 137 (46.1) 36 (29)
3–6 42 (87.5) 160 (53.9) 88 (71)
Hypoglycemia <0.001 0.095 0.021
frequency perception
0–2 32 (66.7) 234 (78.8) 55 (44.4)
3–6 16 (33.3) 63 (21.2) 69 (55.6)
Final score 0.049 0.389 0.091
[4,28) 29 (60.4) 156 (52.5) 52 (41.9)
[28,36) 19 (39.6) 141 (47.5) 72 (58.1)
Notes.
The groups are stratified by medians.
*p-value for comparisons between groups.
LADA, latent autoimmune diabetes of adult; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus.
hypoglycemia (p= 0.021). In the multivariate linear regression analysis (Table S4), T2DM
patients without insulin treatment showed a significantly lower hypoglycemia frequency
perception compared with insulin-treated LADA subjects (p= 0.006). Additionally, the
following conditions increased this measure: T1DM (p= 0.02), female sex (p= 0.001) and
disease duration (p= 0.006).
DISCUSSION
In the current study, we demonstrated that LADA patients presented with lower diabetes-
associated specific and average weighted impact QoL scores than patients with T2DM;
however, we found no differences in terms of present QoL. Insulin treatment had a
negative impact on diabetes-specific QoL, and the subgroup of insulin-treated patients
with LADA did not differ from other insulin-treated groups (T2DM and T1DM) in this
regard; however, the average weighted impact score was poorer in insulin-treated LADA
subjects than in their corresponding T2DM counterparts. The group with the worst values
for this impact score was the subgroup of LADA patients with DR and insulin treatment.
Although there was a significant difference in the DTSQ final score among the groups,
paired comparisons between groups did not reach significant differences; however, there
were differences concerning the hyperglycemia and hypoglycemia frequency perception
among the groups. The LADA patients showed an increased hyperglycemia frequency
perception compared with the T2DM and T1DM groups, which was mainly at the expense
of the insulin-treated LADA group. In contrast, the LADA patients had an improved
hypoglycemia perception frequency compared with the T1DM patients.
To our knowledge, there are no previous studies on QoL and TS in subjects with LADA.
Concerning quality of life, previous studies revealed a lower QoL in patients with type 1
diabetes or insulin-treated type 2 diabetes and in subjects with one or more late diabetic
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complications (Collins et al., 2009). In a previous study by our group, we also found that
patients with T2DM and DR had a lower QoL than those without this complication
(Alcubierre et al., 2014), which is in line with the current findings in patients with LADA.
Our results are also in line with other previous studies that reported that insulin therapy and
diabetic complications were associated with a poorer QoL in patients with T2DM (Bradley
& Speight, 2002; Collins et al., 2009; Depablos-Velasco et al., 2014; Shim et al., 2012; Speight
& Bradley, 2000; Sundaram et al., 2007); however, in a longitudinal study of patients with
T2DM starting insulin therapy, QoL improved six months after the commencement of
insulin therapy (Wilson, Moore & Lunt, 2004). The negative impact of insulin treatment
on LADA patients is associated with a poorer QoL perception, which may be linked to
impaired metabolic control and the delayed initiation of insulin treatment. Furthermore,
Depablos-Velasco et al. (2014) observed that diabetic patients with poor metabolic control
had a low QoL; however, we found no significant differences in terms of glycemic control.
Shim et al. (2012) described that the ADDQoL average weighted impact score was lower
in association with male gender, higher education level and longer disease duration. Other
studies have related lower QoL to advanced age, female sex, lower educational level, obesity,
the presence of diabetic comorbidities, poorer glycemic control and lower socioeconomic
status in the type 1 and type 2 diabetic populations (Ahola et al., 2010; Bradley & Speight,
2002; Collins et al., 2009; Imayama et al., 2011; Nicolucci et al., 2009; Oliva, Fernandez-
Bolanos & Hidalgo, 2012; Shim et al., 2012; Speight & Bradley, 2000; Sundaram et al., 2007).
These findings are similar to our results concerning the presence of complications (i.e., DR),
longer disease duration and waist circumference, all of which were related to a lower QoL.
However, we found a positive relationship between QoL and physical activity in patients
with diabetes. Physical activity is an important component of the lifestyle measures used
to treat patients living with diabetes. Imayama et al. (2011) performed a longitudinal study
of 490 T1DM and 1,147 T2DM patients to investigate the determinants of health-related
QoL (HRQoL). The authors also found a higher HRQoL in patients with a high physical
activity level.
Concerning TS, the results showed a relatively high score despite the negative impact
of diabetes on QoL, which has been reported in previous studies (Bradley & Speight,
2002; Speight & Bradley, 2000; Speight, Reaney & Barnard, 2009). We could not detect
any difference between the LADA patients and the other groups in the DTSQ final
score. Nevertheless, the hyperglycemia frequency perception was worse in the insulin-
treated LADA patients, although glycemic control was not different between the groups.
The increased hyperglycemia frequency perception in the subjects with LADA may be
attributable to previous poorer glycemic control compared with type 1 diabetic patients
under stable control. It is worth noting that the LADA subjects were recruited from a
specialized hospital clinic, where patients are usually referred from primary care because of
poor glycemic control. In contrast, the frequency of hypoglycemia perception was similar
between the LADA and T2DM patients and was clearly increased in T1DM patients.
This finding could be attributed to a higher intensity of insulin treatment in T1DM,
which may be associated with a higher frequency of hypoglycemia in these patients.
Unfortunately, the frequency of previous mild and severe hypoglycemia episodes was not
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assessed. Additionally, as expected from the exposure to insulin treatment, the insulin-
treated LADA patients had an increased frequency of hypoglycemia compared with the
non-insulin treated T2DM patients.
Improved TS has been associatedwith optimal glycemic control (HbA1c≤ 7%) in T2DM
without concomitant complications or insulin treatment (Biderman et al., 2009; Mancera-
Romero et al., 2016). These findings are in line with those reported here. Furthermore,
we found that physical activity showed a positive association with TS, as in our previous
study that involved the subgroup of T2DM patients included in our study (Alcubierre et
al., 2014); however, we could not identify other studies addressing this specific issue in the
diabetic population.
The current study has several limitations. A causal relationship between QoL, TS
and related factors could not be established because of the cross-sectional study design;
however, the variation in the QoL among patients was shown to be strongly influenced
by the characteristics that do not vary over time (Alva et al., 2014). The low number of
patients with LADA that were included is an important limitation. Therefore, the low
number of subjects in the LADA group raises a point of caution regarding the external
validity of the current results. Additionally, a significant number of potential subjects
from the local LADA cohort refused to participate. However, there were no differences
between the participating LADA patients and the non-participating LADA patients in the
proportion of comorbidities that could affect the main study outcomes. Thus, the current
study should be considered an exploratory investigation that raises awareness of the need
for further studies of patient-oriented outcomes in subjects with LADA. Additionally, the
current study compared the QoL and TS of LADA patients with that of patients with the
two main classical types of diabetes. Another limitation arises from the potential selection
bias of the current study hospital setting. Subjects with worse glycemic control are referred
to specialized care for further diagnostic work-up that leads to the final diagnosis of LADA,
while subjects with LADAwho have better glycemic control are likely to remain unidentified
at the primary care level. Therefore, the current results may not be extrapolated to the
whole population of LADA subjects. The issue of poor QoL is very relevant to patients with
LADA who are ultimately referred to specialized care because of unstable glycemic control
and the need for insulin treatment. Finally, mental well-being may have an impact on the
main outcomes evaluated in the current study. Although mood items are included in the
ADDQoL-19 questionnaire, a proper evaluation of emotional or mental well-being was
not performed in this study. This latter issue should be taken into consideration in future
studies of patients with LADA.
CONCLUSIONS
In conclusion, in the current study we found that that LADA patients with DR who
were undergoing insulin treatment had a negative QoL compared with T2DM and T1DM
patients. Furthermore, the LADA patients undergoing insulin treatment perceived a greater
frequency of hyperglycemia than the other diabetic groups. Further research is warranted
to study the status and changes over time in the QoL and TS of patients with LADA in
other settings and with a larger number of patients.
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